Get the Stockscreener App
127.38
0.59%
0.75
After Hours:
127.37
-0.010
-0.01%
Illumina Inc stock is traded at $127.38, with a volume of 960.28K.
It is up +0.59% in the last 24 hours and down -4.15% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$126.63
Open:
$124.44
24h Volume:
960.28K
Relative Volume:
0.49
Market Cap:
$19.48B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
23.31
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
+2.40%
1M Performance:
-4.15%
6M Performance:
+28.28%
1Y Performance:
+55.57%
1-Day Range:
$124.00
$130.00
1-Week Range:
$116.73
$130.00
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
127.38 | 19.36B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 183.71B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.02B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 44.85B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.37B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
UPC refuses early knockout in Illumina–Element dispute - Life Sciences Intellectual Property Review
Illumina, Inc. Announces Board Retirements, Effective May 21, 2026 - MarketScreener
Illumina Announces Board Retirements and New Director Nominee - TipRanks
Illumina (NASDAQ: ILMN) nominates David P. King as three directors retire - Stock Titan
Three Illumina directors are leaving as the company puts David King on its board slate - Stock Titan
Exosome Research Market is Thriving Worldwide | Thermo Fisher Scientific, Illumina Inc, Miltenyi Biotec, QIAGEN - openPR.com
An Illumina milestone powered by our people: 100,000 volunteer hours - Illumina
Illumina Inc. stock rises Tuesday, still underperforms market - MarketWatch
Assenagon Asset Management S.A. Trims Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Inc (ILMN) Stock Price Quote Today & Current Price Chart - Capital.com
Illumina Inc (ILMN) Stock Price Up 3.71% on Mar 30 - GuruFocus
SG Americas Securities LLC Raises Holdings in Illumina, Inc. $ILMN - MarketBeat
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook - GlobeNewswire Inc.
Nilesh Shah joins Illumina as Head of Region, AMEA - MSN
New strong buy stocks for December 4th - MSN
Exchange Traded Concepts Trims Illumina Stock Holdings - National Today
Exchange Traded Concepts LLC Lowers Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know - TradingView
Illumina Inc (ILMN) Shares Down 4.86% on Mar 27 - GuruFocus
Vanguard realigns reporting; subsidiaries to report separately (Illumina, ILMN) - Stock Titan
Wealth Enhancement Advisory Services LLC Grows Stock Position in Illumina, Inc. $ILMN - MarketBeat
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Illumina Inc. Stock: Dominant Player in Genomic Sequencing Faces Competitive and Regulatory Challeng - AD HOC NEWS
Whole Genome Sequencing Market Key Aspects, Benefits, - openPR.com
Connect with Illumina at a major cancer research conference - illumina.com
DRAGEN v4.5: Expanding Accurate Variant Discovery Across the Entire Genome - Illumina
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Argus raises Illumina stock price target to $145 on new products By Investing.com - Investing.com South Africa
Argus raises Illumina stock price target to $145 on new products - Investing.com Canada
Block Trades: Will Illumina Inc benefit from seasonality2026 Macro Impact & Verified Short-Term Trading Plans - baoquankhu1.vn
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures - AD HOC NEWS
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Short Squeeze: Will Illumina Inc benefit from seasonality2026 Closing Moves & Weekly Top Gainers Trade List - baoquankhu1.vn
Assessing Illumina (ILMN) Valuation After New Labcorp And Preventive Genomics Alliances - Sahm
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
Here's why Illumina (ILMN) is a strong growth stock - msn.com
Illumina price gives in to negative pressureForecast today24-03-2026 - Economies.com
US Multiomic Market Set to Boom Rapidly, Witnessing Strong - openPR.com
Illumina : CSR Report (2025 illumina france gender pay gap english) - marketscreener.com
Illumina : CSR Report (2025 illumina gender pay gap uk) - marketscreener.com
Prediction Tool Market Poised for Rapid Growth as AI and Genomics - openPR.com
Canaccord reiterates Hold on Illumina stock amid Roche competition - Investing.com
Nordea Investment Management AB Boosts Stake in Illumina - National Today
Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWS
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - MSN
Swiss Life Asset Management Ltd Purchases 67,772 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):